scholarly journals PCN2 The Relationship of Following Lipid-Lowering Drugs Used With Adjuvant Hormonal Therapy in Breast Cancer Women

2012 ◽  
Vol 15 (7) ◽  
pp. A653
Author(s):  
Y.C. Chang ◽  
S.J. Lin
Keyword(s):  
Breast Cancer ◽  
Hormonal Therapy ◽  
Lipid Lowering ◽  
Adjuvant Hormonal Therapy ◽  
Lipid Lowering Drugs ◽  
Relationship Of ◽  
The Relationship

The relationship between adherence to adjuvant hormonal therapy and survival among low-income, insured women with primary breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11522-e11522
Author(s):  
G. G. Kimmick ◽  
F. Camacho ◽  
W. Hwang ◽  
R. T. Anderson
Keyword(s):  
Breast Cancer ◽  
Hormonal Therapy ◽  
Low Income ◽  
Hormone Receptor ◽  
Adjuvant Hormonal Therapy ◽  
Cancer Specific Survival ◽  
Comorbidity Score ◽  
Regional Stage ◽  
Charlson Comorbidity Score ◽  
The Relationship

e11522 Background: Clinical trials and meta-analyses show that adjuvant hormonal therapy for hormone receptor positive breast cancer significantly decreases risk of death. We explored the relationship between adherence to adjuvant hormonal therapy and death in a low-income, Medicaid-insured population. Methods: Using a Medicaid claims-tumor registry linked database and National Death Index data (NDI), we evaluated adherence to adjuvant hormonal therapy [defined as >80% Medication Possession Ratio (MPR)] and mean six-year overall and cancer-specific survival by local versus regional stage for all female breast cancer diagnosed in years 2000–2002, in North Carolina. The Kaplan-Meier and Cox Proportional Hazards models were used to determine the role of adherence on cancer-specific survival. Models were adjusted for age, race, Charlson comorbidity score, number of prescription medications, type of surgery, use of radiation therapy, prior chemotherapy, hormone receptor status (positive or unknown). Results: The final sample consisted of 1,042 cases [ages range 29–97 years (mean 65.9 years; 56% Caucasian; mean Charlson comorbidity score 4.1 (SD 2.9); 680 local and 362 regional stage], of which 732 filled a prescription for adjuvant hormonal therapy within the year after breast cancer diagnosis. Filling a prescription for adjuvant hormonal therapy, versus not, was not significantly associated with cancer-related death: HR 1.04 (95% CI 0.66 - 1.64) overall; HR 0.75 (95% CI 0.39 - 1.43) for local stage and HR 1.01 (95% CI 0.51 - 2.00) for regional stage. However, adherence in the highest quartile (MPR>95) is associated with an increase in mortality risk. Conclusions: In this low income insured group of breast cancer patients, no statistically significant association was found between death rates and use of adjuvant hormonal therapy. However, an unexpected association between very high adherence and increase in mortality was found. This may reflect methodological limitations of claims data involving bias and unidentified patient risk. More research is needed to explore reasons for higher mortality among low-income women with high medication adherence. [Table: see text]

The role of the clinical pharmacist in guiding adjuvant hormonal therapy in patients with breast cancer

2021 ◽  
pp. 107815522110293
Author(s):  
Amanda V Pirolli ◽  
Tatiana Brusamarello ◽  
Stella S Everton ◽  
Vânia M S Andrzejevski
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Hormonal Therapy ◽  
Clinical Pharmacist ◽  
Tertiary Care ◽  
Structured Interview ◽  
Care Hospital ◽  
Adjuvant Hormonal Therapy ◽  
Breast Cancers

Breast cancer is the most prevalent type of cancer among women, affecting about 2.1 million worldwide and is responsible for the highest number of cancer-related deaths among women. Approximately 80% of breast cancers express on the surface of hormone receptor cells, such as progesterone and estrogen. In these cases, Adjuvant Hormonal Therapy (AHT) is indicated for a period of five to ten years and consists of taking a daily oral pill. The two most used drugs in AHT are tamoxifen and Aromatase Inhibitors. One of the issues most faced by individuals who are subjected to long periods of treatment is the lack of medication adherence and, consequently, therapeutic inefficiency. It is believed that the monitoring by the pharmacist can contribute to the reduction of errors inherent to the medication, making the treatment more effective and improving the patient's quality of life. The present study aimed to know the perception of patients who live with breast cancer and who do AHT in relation to the educational performance of the clinical pharmacist. This is a qualitative, descriptive and exploratory study, carried out from March to October 2020, with 15 women undergoing treatment at the oncology unit of a tertiary-care hospital in south of Brazil. The data were obtained through a semi-structured interview using an instrument composed of two parts, one referring to the characterization of the participants and the other with the guiding question of the research: "How do you perceive the role of the pharmacist in relation to the guidelines for the use of adjuvant hormonal therapy?". The method of theoretical saturation was used to perform the sample closure and the thematic analysis was used to analyze the data. The participants were between 32 and 74 years old, seven were on tamoxifen therapy and eight on anastrozole, ten were on the first year of treatment, two on the second and three on the third year. The themes that emerged were: pharmacist-patient interaction as a safety factor in hormone therapy; role of the pharmacist in the development of strategies for self-management of the patients during hormone therapy; and, challenges for the pharmacist in relation to hormone therapy through continued guidance. It was evident that the pharmacist's educational action encouraged the participants to carry out the treatment in a more confident and assertive manner according to their particularities and beliefs.

The relationship of self-acceptance with decision making duration in cancer patient to perform mastectomy

2021 ◽  
pp. 1-5
Author(s):  
Ayu Ratuati Setiawan ◽  
Feny Tunjungsari ◽  
Mochamad Aleq Sander
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Cross Sectional ◽  
Abnormal Growth ◽  
Self Acceptance ◽  
Observation Method ◽  
Relationship Of ◽  
The Relationship

BACKGROUND: Cancer is a disease caused by abnormal growth of body cells that turn malignant and continue to grow uncontrollably. One of the treatments for breast cancer is mastectomy. The quickness of decision-making determines the survival rate of prognosis patients. OBJECTIVE: This study aimed to determine the relationship of self-acceptance with decision-making duration in cancer patients to perform a mastectomy. METHODS: An analytic observation method with cross-sectional design. The samples were taken by purposive sampling method with 50 samples of breast cancer patients. Data collected include age, last level of education, marital status, profession, stage of cancer during mastectomy, self-acceptance score, and decision-making duration to perform a mastectomy. RESULTS: The data analyzed with the Kruskal–Wallis test. The test showed the relationship of self-acceptance (p = 0.027) with decision-making duration in breast cancer patients to perform a mastectomy. CONCLUSION: In Conclusion, there is a relationship of self-acceptance with decision-making duration in breast cancer patients to perform a mastectomy.

The relationship of plasma 7α-hydroxy dehydroepiandrosterone to disease stage and adrenal androgens in breast cancer patients

1980 ◽  
Vol 16 (2) ◽  
pp. 223-228 ◽  
Author(s):  
S.J.M. Skinner ◽  
R.A.F. Couch ◽  
S. Thambyah ◽  
R.J. Dobbs ◽  
S.M. Jordan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Disease Stage ◽  
Breast Cancer Patients ◽  
Adrenal Androgens ◽  
Relationship Of ◽  
The Relationship

The relationship of estrogen receptor status to DNA ploidy in breast cancer

Surgery Today ◽  
1992 ◽  
Vol 22 (2) ◽  
pp. 105-109 ◽  
Author(s):  
Atsuo Tsuchiya ◽  
Mitsuhiro Nihei ◽  
Yoshiro Ando ◽  
Shinichi Suzuki ◽  
Izo Kimijima ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Dna Ploidy ◽  
Estrogen Receptor Status ◽  
Receptor Status ◽  
Relationship Of ◽  
The Relationship

scholarly journals The Relationship of Age and Postoperative Pain in Women after Surgery for Breast Cancer

2018 ◽  
Vol 19 (4) ◽  
pp. 348-353
Author(s):  
Christina Kudach ◽  
Colleen Dunwoody ◽  
Susan Wesmiller
Keyword(s):  
Breast Cancer ◽  
Postoperative Pain ◽  
Relationship Of ◽  
The Relationship

Exploring the influence of multiple variables on the relationship of age to quality of life in women WITH BREAST CANCER

1992 ◽  
Vol 45 (5) ◽  
pp. 473-485 ◽  
Author(s):  
Patricia A. Ganz ◽  
J.Jack Lee ◽  
Myung-Shin Sim ◽  
Margaret L. Polinsky ◽  
C.Anne Coscarelli Schag
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Multiple Variables ◽  
Relationship Of ◽  
The Relationship
Sign in / Sign up

Export Citation Format

Share Document